Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The first aim of the study is to prove that after starting the therapy with crushed tablets,
the platelet inhibition will be as expected after starting therapy with intact tablets.
Gurbel et al. showed that 100% of the patients on ticagrelor treatment have a decrease from
baseline platelet aggregation of >10% 4 hours after last maintenance dose. So the
investigators expect that after 3 days of treatment, all of our patients will have a closing
time of more than 106seconds.
The investigators will observe two different clinical conditions of Acute Coronary Syndrome.
First after semi-urgent coronary artery bypass graft (CABG) surgery, secondly in patients
after cardiac arrest.
Both are clinical situations in which crushed tablets are needed to give. The second
objective is to determine plasma concentrations of Ticagrelor and AR-C124910XX (active
metabolite of ticagrelor) in these two patient populations after receiving 180mg or 90mg
start-dose. Determination of plasma concentrations is done after protein precipitation, by
using liquid chromatography with mass spectrometry detection. Measurements will be determined
before intake (0h) and at 0,5; 1; 2; 4; 8; 24h and at day 4 +4h.7 The first 24h this will be
a crushed tablet and 4 hours after the first intake at day 4 of therapy, this will be a non
crushed tablet.